Evidence map›Paper›PMID 40586312›Full record

ArticleNucleic acids research2025

ERH regulates type II interferon immune signaling through post-transcriptional regulation of JAK2 mRNA.

Adrian Soderholm, Milica Vunjak, Melanie de Almeida, Niko Popitsch, Nadezda Podvalnaya, Pablo Araguas-Rodriguez, Sara Scinicariello, Emily Nischwitz, Falk Butter, René F Ketting and 4 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Adrian SoderholmMax Perutz Labs, Vienna BioCenter Campus (VBC), Dr. -Bohrgasse 9, 1030, Vienna, Austria.
Milica VunjakMax Perutz Labs, Vienna BioCenter Campus (VBC), Dr. -Bohrgasse 9, 1030, Vienna, Austria.
Melanie de AlmeidaVienna BioCenter PhD Program, Doctoral School of the University at Vienna and Medical University of Vienna, Vienna BioCenter (VBC), 1030, Vienna, Austria.
Niko PopitschMax Perutz Labs, Vienna BioCenter Campus (VBC), Dr. -Bohrgasse 9, 1030, Vienna, Austria.ORCID 0000-0002-2318-2391
Nadezda PodvalnayaInstitute of Molecular Biology (IMB), Johannes Gutenberg University (JGU), D-55128, Mainz, Germany.
Pablo Araguas-RodriguezMax Perutz Labs, Vienna BioCenter Campus (VBC), Dr. -Bohrgasse 9, 1030, Vienna, Austria.
Sara ScinicarielloMax Perutz Labs, Vienna BioCenter Campus (VBC), Dr. -Bohrgasse 9, 1030, Vienna, Austria.
Emily NischwitzQuantitative Proteomics, Institute of Molecular Biology, D-55128 Mainz, Germany.
Falk ButterQuantitative Proteomics, Institute of Molecular Biology, D-55128 Mainz, Germany.ORCID 0000-0002-7197-7279
René F KettingInstitute of Molecular Biology (IMB), Johannes Gutenberg University (JGU), D-55128, Mainz, Germany.ORCID 0000-0001-6161-5621
Stefan L AmeresMax Perutz Labs, Vienna BioCenter Campus (VBC), Dr. -Bohrgasse 9, 1030, Vienna, Austria.ORCID 0000-0002-8248-3098
Michaela Müller-McNicollInstitute of Molecular Biosciences, Goethe University Frankfurt, D-60348, Frankfurt am Main, Germany.ORCID 0000-0002-7174-8310
Johannes ZuberResearch Institute of Molecular Pathology (IMP), Vienna BioCenter Campus (VBC), Campus-Vienna-Biocenter 1, 1030, Vienna, Austria.ORCID 0000-0001-8810-6835
Gijs A VersteegMax Perutz Labs, Vienna BioCenter Campus (VBC), Dr. -Bohrgasse 9, 1030, Vienna, Austria.ORCID 0000-0002-6150-2165

Funding

Austrian Academy of SciencesAustrian Research Promotion Agency FFG-852936Austrian Science Fund 10.55776/F79Austrian Science Fund 10.55776/P30231Austrian Science Fund 10.55776/P30415Austrian Science Fund 10.55776/P36572Austrian Science Fund 10.55776/P36945Austrian Science Fund 10.55776/W1261Österreichische Forschungsförderungsgesellschaft FFG-852936
6 · The paper itself

Abstract

Type II interferon (IFNγ) signaling is essential for innate immunity and critical for effective immunological checkpoint blockade in cancer immunotherapy. Genetic screen identification of post-transcriptional regulators of this pathway has been challenging since such factors are often essential for cell viability. Here, we utilize our inducible CRISPR/Cas9 approach to screen for key post-transcriptional regulators of IFNγ signaling, and in this way, we identify ERH and the ERH-associated splicing and RNA export factors MAGOH, SRSF1, and ALYREF. Loss of these factors impairs post-transcriptional mRNA maturation of JAK2, a crucial kinase for IFNγ signaling, resulting in abrogated JAK2 protein levels and diminished IFNγ signaling. Further analysis highlights a critical role for ERH in preventing intron retention in AU-rich regions in specific transcripts, such as JAK2. This regulation is markedly different from previously described retention of GC-rich introns. Overall, these findings reveal that post-transcriptional JAK2 processing is a critical rate-limiting step for the IFNγ-driven innate immune response.

Indexed as

Interferon-gammaJanus Kinase 2RNA, MessengerRNA Processing, Post-TranscriptionalAnimalsCRISPR-Cas SystemsHEK293 CellsHumansImmunity, InnateIntronsRNA SplicingSerine-Arginine Splicing FactorsSignal TransductionInterferon-gammaJAK2 protein, humanJanus Kinase 2RNA, MessengerSerine-Arginine Splicing Factors

Identifiers

PMID40586312
PMCPMC12207402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.